SNTI

Senti Biosciences Holdings, Inc.
CAPPED RATING

Senti Biosciences Holdings, Inc. (SNTI) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
C
Factor Score 2.4 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
F
Factor Score 0.4 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA -0.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -67.4%
Price Return 12M -92.6%
Catalyst Signal 0.00
Market Cap $5.4M
TTM Revenue $55.0K
Price / Sales 97.9
ROE -466.5%

Historical Factor Score Progression

Held D+ for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C (2.4) C- (2.0) F (0.4) F (0.6) C+ (2.6) D+ (1.6)
2026-11-08 C (2.3) C- (2.0) F (0.4) D- (0.8) C+ (2.6) D+ (1.6)
2026-11-01 C (2.3) C- (1.9) F (0.4) D- (0.8) C+ (2.7) D+ (1.6)
2026-10-25 C (2.3) C- (1.9) F (0.4) D- (0.8) C+ (2.6) D+ (1.6)
2026-10-18 C (2.3) C- (1.9) F (0.4) D- (0.8) C+ (2.6) D+ (1.6)
Page 1 of 4